Skip to content

Nebivolol Versus Carvedilol in Patients With Heart Failure

Effects of Nebivolol Versus Carvedilol in Hypertensive Patients With Chronic Heart Failure

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00511888
Enrollment
160
Registered
2007-08-06
Start date
2004-01-31
Completion date
2007-06-30
Last updated
2008-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure, Hypertension

Keywords

chronic heart failure, hypertension, beta blockers

Brief summary

BACKGROUND Beta-blockers improve left ventricular (LV) systolic function and prognosis in patients with chronic heart failure. Both carvedilol and nebivolol have hemodynamic and clinical benefits in chronic heart failure (CHF), but it is unknown whether their pleiotropic properties may play a role in different subgroups of patients with CHF. OBJECTIVE: To compare the effects of nebivolol and carvedilol on LV function and clinical outcome in patients with chronic heart failure and reduced LV systolic function. METHODS: 160 hypertensive CHF patients, LV ejection fraction (EF) 40% and in New York Heart Association (NYHA) functional class II or III were randomly assigned to receive carvedilol or nebivolol therapy for 24 months. At baseline and after 24 months of treatment, all patients underwent clinical evaluation: echocardiogram and 6-minute walking test.

Interventions

None listed

Sponsors

IRCCS San Raffaele
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
53 Years to 76 Years
Healthy volunteers
No

Inclusion criteria

* left ventricular ejection fraction (LVEF) \< 40%; * symptomatic heart failure with functional New York Heart Association (NYHA) class II or III; * arterial hypertension with systolic blood pressure \>140 mmHg and diastolic blood pressure \>85 mmHg; * clinical stability without hospital admission for heart failure in the previous 3 months.

Exclusion criteria

* history of asthma or severe chronic obstructive pulmonary disease; * severe liver or kidney diseases; * second-degree or third degree heart block without a permanent pacemaker, * sick sinus syndrome, heart rate \<60 beat/min, systolic blood pressure \<90 mmHg.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026